| Epidemiology and risk factors for bipolar disorder |
35 |
| The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses |
21 |
| Genetic risk factors for eating disorders: an update and insights into pathophysiology |
15 |
| Medication nonadherence in bipolar disorder: a narrative review |
15 |
| Frontotemporal dementia: latest evidence and clinical implications |
13 |
| Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment |
12 |
| Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec |
10 |
| Assessment and management of sexual dysfunction in the context of depression |
10 |
| Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation |
10 |
| Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression |
10 |
| Cannabidiol as a potential treatment for psychosis |
10 |
| The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder |
9 |
| The emerging role of omega-3 fatty acids as a therapeutic option in neuropsychiatric disorders |
8 |
| Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis |
6 |
| Patients' attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators |
6 |
| Neuromodulation for the treatment of eating disorders and obesity |
5 |
| Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders |
5 |
| Treatment of psychoses in patients with epilepsy: an update |
4 |
| Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective |
4 |
| Treatment of adult ADHD: a clinical perspective |
4 |
| When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity |
4 |
| Trim the fat: the role of omega-3 fatty acids in psychopharmacology |
4 |
| Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature |
4 |
| Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study |
4 |
| Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial |
4 |
| A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine |
3 |
| Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia |
3 |
| Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques |
3 |
| The relationship between nicotine and psychosis |
3 |
| Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013 |
3 |
| Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil |
2 |
| Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service |
2 |
| First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse |
2 |
| Rethinking the spectrum of mood disorders: implications for diagnosis and management - Proceedings of a symposium presented at the 30th Annual European College of Neuropsychopharmacology Congress, 4 September Paris, France |
2 |
| Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study |
2 |
| The antipsychotic landscape: dopamine and beyond |
2 |
| The association between hormones and antipsychotic use: a focus on postpartum and menopausal women |
2 |
| Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study |
1 |
| Dilemmas in the treatment of early-onset first-episode psychosis |
1 |
| Psychotic disorders in late life: a narrative review |
1 |
| What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? |
1 |
| 6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder |
1 |
| Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidance |
1 |
| Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy |
1 |
| Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics |
1 |
| Clozapine, HIV and neutropenia: a case report |
0 |
| Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients |
0 |
| Effectiveness of paliperidone long-acting injection in clinical practice |
0 |
| Acetylcholinesterase inhibitors in treatment-resistant psychotic depression |
0 |
| Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients |
0 |
